End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.84 CNY | -2.12% | -2.60% | -41.13% |
06:35am | Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial | MT |
Apr. 24 | Walvax Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.13% | 3.12B | |
-2.86% | 87.31B | |
+2.63% | 40.86B | |
-22.43% | 29.36B | |
+58.56% | 24.49B | |
-14.69% | 17.31B | |
-18.63% | 11.62B | |
-15.61% | 11.31B | |
-44.02% | 11.26B | |
+5.17% | 8.31B |
- Stock Market
- Equities
- 300142 Stock
- News Walvax Biotechnology Co., Ltd.
- Walvax Biotechnology Gets Approval For Third Phase Trial Into COVID-19 Vaccine